SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    A. Prica, K. Chan, M. Cheung, Combined modality therapy versus chemotherapy alone as an induction regimen for primary central nervous system lymphoma: a cost-effectiveness analysis, Neuro-Oncology, 2014, 16, 10, 1384

    CrossRef

  2. 2
    C. L. Attard, A. N. Pepper, S. T. Brown, M. F. Thompson, P.-O. Thuresson, S. Yunger, S. Dent, A. H. Paterson, G. A. Wells, Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada, Journal of Medical Economics, 2014, 1

    CrossRef

  3. 3
    Yu Ko, Yong-Sheng Gwee, Yu-Chu Huang, Joen Chiang, Alexandre Chan, Costs and Length of Stay of Drug-Related Hospital Admissions in Cancer Patients, Clinical Therapeutics, 2014, 36, 4, 588

    CrossRef

  4. 4
    K. Krzemieniecki, P. Sevelda, F. Erdkamp, M. Smakal, M. Schwenkglenks, J. Puertas, A. Trojan, Z. Szabo, K. Bendall, J. Maenpaa, Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy—findings from clinical practice, Supportive Care in Cancer, 2014, 22, 3, 667

    CrossRef

  5. 5
    H F Burnett, R Tanoshima, W Chandranipapongse, P Madadi, S Ito, W J Ungar, Testing for thiopurine methyltransferase status for safe and effective thiopurine administration: a systematic review of clinical guidance documents, The Pharmacogenomics Journal, 2014, 14, 6, 493

    CrossRef

  6. 6
    C. O'Brien, E. Fogarty, C. Walsh, O. Dempsey, M. Barry, M.J. Kennedy, L. McCullagh, The cost of the inpatient management of febrile neutropenia in cancer patients – a micro-costing study in the Irish healthcare setting, European Journal of Cancer Care, 2014, 23, 6
  7. 7
    N. Lathia, P. K. Isogai, C. D. Angelis, T. J. Smith, M. Cheung, N. Mittmann, J. S. Hoch, S. Walker, Cost-Effectiveness of Filgrastim and Pegfilgrastim as Primary Prophylaxis Against Febrile Neutropenia in Lymphoma Patients, JNCI Journal of the National Cancer Institute, 2013, 105, 15, 1078

    CrossRef

  8. 8
    Nina Lathia, Pierre K. Isogai, Scott E. Walker, Carlo De Angelis, Matthew C. Cheung, Jeffrey S. Hoch, Nicole Mittmann, Eliciting patients’ preferences for outpatient treatment of febrile neutropenia: a discrete choice experiment, Supportive Care in Cancer, 2013, 21, 1, 245

    CrossRef

  9. 9
    Matthias Schwenkglenks, Kate Louise Bendall, Alena M. Pfeil, Zsolt Szabo, Ruth Pettengell, External validation of a risk model of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma, Leukemia & Lymphoma, 2013, 54, 11, 2426

    CrossRef

  10. 10
    Camille C. Gunderson, Regina Farrell, Brian C. Dinh, Eric D. Thomas, Sara K. Vesely, Jacob K. Lauer, Lydia Kao, Sheeva Chopra, D. Scott McMeekin, Kathleen N. Moore, Inpatient versus outpatient management of neutropenic fever in gynecologic oncology patients: Is risk stratification useful?, Gynecologic Oncology, 2013, 130, 3, 411

    CrossRef

  11. 11
    John Hornberger, Gary H. Lyman, Rebecca Chien, Neal J. Meropol, A Multigene Prognostic Assay for Selection of Adjuvant Chemotherapy in Patients with T3, Stage II Colon Cancer: Impact on Quality-Adjusted Life Expectancy and Costs, Value in Health, 2012, 15, 8, 1014

    CrossRef

  12. 12
    Oliver Teuffel, Lillian Sung, Advances in management of low-risk febrile neutropenia, Current Opinion in Pediatrics, 2012, 24, 1, 40

    CrossRef

  13. 13
    M. Elligsen, S. A. N Walker, S. E. Walker, F. LePiane, N. Lathia, C. De’Angelis, A. Simor, Comparison of mortality between nosocomial and community-acquired febrile neutropenia patients treated initially with cefazolin plus tobramycin: retrospective chart review, European Journal of Clinical Microbiology & Infectious Diseases, 2012, 31, 6, 1141

    CrossRef

  14. 14
    Shannon L. Michels, Rich L. Barron, Matthew W. Reynolds, Karen Smoyer Tomic, Jingbo Yu, Gary H. Lyman, Costs Associated with Febrile Neutropenia in the US, PharmacoEconomics, 2012, 30, 9, 809

    CrossRef

  15. 15
    Nuttapong Ngamphaiboon, Tracey L. O’Connor, Pooja P. Advani, Ellis G. Levine, Ellen B. Kossoff, Febrile neutropenia in adjuvant docetaxel and cyclophosphamide (TC) with prophylactic pegfilgrastim in breast cancer patients: a retrospective analysis, Medical Oncology, 2012, 29, 3, 1495

    CrossRef

  16. 16
    O. Teuffel, S. Cheng, M. C. Ethier, C. Diorio, J. Martino, C. Mayo, R. Wing, L. Sung, S. M. H. Alibhai, Health-related quality of life anticipated with different management strategies for febrile neutropenia in adult cancer patients, Supportive Care in Cancer, 2012, 20, 11, 2755

    CrossRef

  17. 17
    Ruth Pettengell, Hans E. Johnson, Pieternella J. Lugtenburg, Antonio Salar Silvestre, Ulrich Dührsen, Francesca G. Rossi, Matthias Schwenkglenks, Kate Bendall, Zsolt Szabo, Ulrich Jaeger, Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma, Supportive Care in Cancer, 2012, 20, 3, 647

    CrossRef

  18. 18
    Tallal Younis, Daniel Rayson, Kara Thompson, Primary G-CSF prophylaxis for adjuvant TC or FEC-D chemotherapy outside of clinical trial settings: a systematic review and meta-analysis, Supportive Care in Cancer, 2012, 20, 10, 2523

    CrossRef

  19. 19
    O Teuffel, E Amir, S Alibhai, J Beyene, L Sung, Cost effectiveness of outpatient treatment for febrile neutropaenia in adult cancer patients, British Journal of Cancer, 2011, 104, 9, 1377

    CrossRef